Yakup Ergün/obdh.com.tr
Apr 6, 2025, 08:25
Yakup Ergün: A great review series on targetable mutations in NSCLC
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X:
“A great review series on targetable mutations in NSCLC has been published in the ACS Journal Cancer.”
EGFR
Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer
Authors: Jinyong Kim, et al.
RET
Treatment of non–small cell lung cancer with RET rearrangements
Authors: Hui Jing Hoe, Benjamin J. Solomon.
HER2
Targeting HER2 in Lung Cancers: Evolving treatment landscape and drug development strategies.
Authors: Daniel Reinhorn, et al.
BRAF
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice.
Authors: Claudia Parisi, David Planchard.
MET
From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping
Authors: Wiktoria Bogdanska PharmD, Paul K.Paik.
KRAS G12C
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Authors: Khvaramze Shaverdashvili, Timothy F. Burns
ROS1
Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future direction.
Authors: Antoine Desilets, et al.
ALK
Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
Authors: Beatriz E. Jimenez Munarriz, et al.
More posts featuring Yakup Ergün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 6, 2025, 08:25
Apr 6, 2025, 07:44
Apr 6, 2025, 07:34
Apr 6, 2025, 06:41